Shanghai Hengrui Company Profile
What is the competitive landscape for SHANGHAI HENGRUI
SHANGHAI HENGRUI has two approved drugs.
Drugs and US Patents for Shanghai Hengrui
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shanghai Hengrui | SEVOFLURANE | sevoflurane | LIQUID;INHALATION | 203793-001 | Nov 3, 2015 | AN | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Shanghai Hengrui | DESFLURANE | desflurane | LIQUID;INHALATION | 208234-001 | Feb 26, 2018 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

